Semax 10 mg | Research Compound
At the 10mg concentration, Semax is studied for its dose-dependent impact on neurochemical regulation and its prolonged influence on the central nervous system. This concentration is frequently used in research to observe the saturation limits of BDNF and NGF signaling and the compound’s ability to mitigate significant neurological stressors. Researchers investigate this higher dosage to analyze the depth of its neuroprotective window and its potential to stabilize cognitive markers during periods of high-intensity mental load.
Findings from early-stage clinical trials have reported:
- Dose-dependent increases in the concentration of neurotrophic factors observed across study groups
- Enhanced recovery rates of neurological function following ischemic events reported in research cohorts
- Marked improvements in information processing and cognitive flexibility noted in experimental models
- Sustained modulation of the serotonergic and dopaminergic pathways observed during the study period
Researchers study the higher concentration of Semax to explore the duration of its metabolic impact on the brain. By analyzing the interplay between ACTH analogues and neuronal gene expression, it serves as a specialized tool for investigating the management of acute neurological trauma and the preservation of higher-order brain functions. Its multi-receptor profile makes it a primary focus for research into advanced neurotherapy.
Available Formats:
This compound is available in a 9ml premixed spray bottle, providing a stable solution for precise administration in research settings.
Used solely for in vitro experiments and cannot be:
- Used in clinical trials involving humans
- Administered to humans as part of an experiment or investigation
- Supplied to another party for human investigational use
| IDENTIFICATION | |
| Product Name | Semax 5 mg / 10 mg |
| Catalogue Number | RP-SEMAX-01 |
| CAS Number | 80714-61-0 |
| Molecular Weight (g/mol) | 813.9 g/mol |
| Molecular Formula | C37H51N9O10 |
| Peptide Sequence | Met-Glu-His-Phe-Pro-Gly-Pro |
| PHYSICAL AND CHEMICAL PROPERTIES | |
| Active Ingredient | Semax |
| Appearance | White to off-white lyophilised powder |
| Melting Point | Not applicable (decomposes before melting) |
| ANALYTICAL AND QUALITY CONTROL | |
| Mass Spectrum | Conforms to specification |
| Structural Confirmation | Consistent with theoretical structure / sequence |
| RESEARCH USE AND SAFETY | |
| Caution | Handle using appropriate PPE and in compliance with relevant laboratory safety standards. |
| Intended Use | For laboratory research use only. Not for human or veterinary use. |
| Hazard Classification | Not classified as hazardous under GHS for research quantities |
| STORAGE, HANDLING AND STABILITY | |
| Storage Temperature, Opened | -20 °C, minimise freeze–thaw cycles |
| Storage Temperature, Unopened | -20 °C recommended for long-term storage |
| Shelf Life | 2 years unopened under recommended conditions |
| Reconstitution Stability | Stable for up to 28 days at 2–8 °C in aqueous solution under sterile conditions |
Certificate of Analysis – Semax (99% Purity Verified)
| COMPOUND IDENTIFICATION | |
| Product Name | Semax (10mg Spray) |
| Batch / Reference ID | SX101204 |
| Sample Form | White powder in glass vial |
| ANALYTICAL RESULTS | |
| Chemical Purity | 99% (Verified) |
| Measured Content | 9.72mg (± 0.05mg) |
| Test Method | HPLC (High-Performance Liquid Chromatography) |
| LABORATORY TESTING INFORMATION | |
| Analysis Period | 06 Feb 2026 – 10 Feb 2026 |
| Laboratory Order # | 100012226 |
| QUALITY ASSURANCE | |
| Quality Testing Standards | All River Peptides products undergo batch-level laboratory analysis to verify compound identity and confirm purity levels. Learn more on our Quality Testing & Purity Verification page. |
Related Products
AOD-9604 (Fragment 176-191)
